PEN Price Prediction Next Week
Technical Analysis: Based on the latest data, PEN is currently trading at $263.69 with RSI(14) at 51.16, indicating a neutral momentum. The stock is trading above both its 20-day moving average ($265.25) and 200-day moving average ($211.89), suggesting a long-term uptrend but short-term consolidation.
News Sentiment Analysis: Recent news shows UBS initiated coverage on Penumbra (PEN) with a Buy rating and a price target of $305 on January 21, 2025. This indicates positive institutional sentiment with a potential upside of about 15.7% from current levels.
Fibonacci Analysis: Key Fibonacci levels for next week:
- Resistance 3: $282.53
- Resistance 2: $276.43
- Resistance 1: $272.66
- Pivot: $266.56
- Support 1: $260.46
- Support 2: $256.69
- Support 3: $250.59
Price Prediction for Next Week: Based on technical indicators and Fibonacci levels:
- Bullish scenario (60% probability): Price likely to test R1 at $272.66
- Neutral scenario (30% probability): Consolidation between $260-$267
- Bearish scenario (10% probability): Drop to S1 at $260.46
Trading Recommendation: BUY with entry at current level ($263.69) with initial target at R1 ($272.66). Set stop loss at S2 ($256.69) to limit downside risk. The positive analyst coverage and technical setup suggest upward momentum is likely to continue.
PEN Similar Chart Price Prediction
The price of PEN is predicted to go up -9.36%, based on the high correlation periods with GLYC. The similarity of these two price pattern on the periods is 98.14%.
PEN
GLYC
Down: -9.36%Similarity: 98.14%
PEN Revenue Forecast
PEN EPS Forecast
PEN FAQs
What is bull’s view on PEN?
What is bear's view on PEN?
What is PEN revenue forecast for next quarter？
What is PEN eps forecast for next quarter？
PEN Analyst's Forecast
Priya Sachdeva
UBS
Strong Buy
2025-01-21
Price Target
$305
Upside
+13.72%
UBS initiated coverage of Penumbra with a Buy rating and $305 price target. The firm sees the company's ongoing new product launch cycle delivering "clear line of sight" into sales and earnings upside drivers over the near-to-medium term. The shares should continue to trade at a premium versus its high-growth Smid-Cap medical technology peers given their "top-tier growth and margin profile," the analyst tells investors in a research note.
Richard Newitter
Truist Securities
Strong Buy
2024-12-18
Price Target
$240 → $285
Upside
+19.3%
Joanne Wuensch
Citigroup
Hold
2024-12-11
Price Target
$200 → $245
Downside
-3.41%
